🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise around the world, with figures suggesting more than 82 million new cases annually. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Health officials are increasingly worried about the rise in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts anticipate that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, gained clearance in the same week. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This approval marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

Based on findings published in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This establishes an similar efficacy with the typical regimen, which uses two antibiotics. The study involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared optimism. Access to a easy-to-administer therapy like this is seen as a "game-changer" for gonorrhoea control. This is deemed crucial to lessen the impact of the infection for patients and to prevent the spread of untreatable gonorrhoea globally.